Mithra Pharmaceuticals S.A.
MITPFOTCHealthcare
$23.90
+$17.15(+254.07%)
Market Cap$1.6B
P/E Ratio—
52W High$23.9
52W Low$6.75
Mithra Pharmaceuticals S.A.（MITPF）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · MITPF · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($173.50M) | ($59.62M) | ($116.88M) | ($92.09M) | ($26.56M) |
| Depreciation & Amort. | $12.21M | $11.94M | $10.43M | $9.87M | $5.78M |
| Stock-Based Comp. | $4.54M | $1.98M | $1.06M | $7.27M | $4.90M |
| Change in Working Capital | $0.00M | ($31.13M) | $6.15M | ($11.45M) | ($52.99M) |
| Net Cash from Operations | ($2.18M) | ($66.68M) | ($86.15M) | ($83.53M) | ($50.15M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | ($25.66M) | ($21.18M) | ($16.23M) | ($15.46M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $3.45M | ($25.49M) | ($54.68M) | ($16.21M) | ($20.45M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $45.42M | $25.80M | $121.53M | $1.20M |
| Net Cash from Financing | ($20.54M) | $87.73M | $35.01M | $188.69M | $1.37M |
| Free Cash Flow | |||||
| Free Cash Flow | ($2.18M) | ($92.34M) | ($107.33M) | ($99.76M) | ($65.60M) |
| FCF Margin %(computed) | -5.44% | -137.83% | -473.50% | — | -67.97% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · EUR · M
深入了解Mithra Pharmaceuticals S.A.
关于Mithra Pharmaceuticals S.A.（MITPF）现金流量表
Mithra Pharmaceuticals S.A. 2023财年经营活动现金流($0.00B)，自由现金流($0.00B)（FCF利润率-5.44%），资本支出$0.00B。
常见问题
MITPF · 4 问Mithra Pharmaceuticals S.A. 2023财年自由现金流($0.00B)，同比up97.6%。
MITPF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10